Larisa Greenberg
Expertise in
35
conditions

Dr. Larisa Greenberg

Oncology | Hematology
314 East North Avenue, 
Pittsburgh, PA 
Offers Telehealth
Expertise in
35
conditions
314 East North Avenue, 
Pittsburgh, PA 

Overview

Dr. Greenberg is a medical oncologist who specializes in head and neck cancers, as well as melanoma and sarcoma. She has decades of experience treating patients with cancer, clinical research, and teaching. She is a member of American Society of Clinical Oncology, Society of Neuro-Oncology, Pennsylvania Society of Oncology and Hematology, American Medical Association, and Pennsylvania Medical Society.

Dr. Greenberg is highly rated in 35 conditions, according to our data. Her clinical expertise encompasses Laryngeal Cancer, Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Endoscopy.

Dr. Greenberg is board certified in Medical Oncology, American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in PA

Board Certifications

Medical Oncology, American Board Of Internal Medicine

Fellowships

Wayne State University Health Center

Hospital Affiliations

Canonsburg General Hospital
Allegheny Valley Hospital
Ahn Wexford Hospital
Allegheny General Hospital
West Penn Hospital

Languages Spoken

English
Russian
Ukrainian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
314 East North Avenue, Pittsburgh, PA 15212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

6 Total Publications

Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.
Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.
Journal: Current oncology (Toronto, Ont.)
Published: March 10, 2025
Similar Doctors
Expertise in
4
conditions
Dr. Kelly M. Bailey
Hematology | Oncology
Expertise in
4
conditions
Dr. Kelly M. Bailey
Hematology | Oncology
Referral may be required

UPMC Children's Hospital Of Pittsburgh

4401 Penn Ave, 
Pittsburgh, PA 
 (2.7 miles away)
412-692-6644
Languages Spoken:
English
See accepted insurances

Kelly Bailey is a Hematologist and an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Bailey is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.

Expertise in
47
conditions
Dr. David M. Friedland
Hematology | Oncology
Expertise in
47
conditions
Dr. David M. Friedland
Hematology | Oncology
Referral may be required

Office

2 Hot Metal St, 
Pittsburgh, PA 
 (3.0 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

David Friedland is a Hematologist and an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Friedland is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Expertise in
17
conditions
Dr. Dulabh K. Monga
Oncology | Hematology
Expertise in
17
conditions
Dr. Dulabh K. Monga
Oncology | Hematology
Referral may be required

AHN Cancer Institute-Med Onc & Infusions At Allegheny General Hospital

314 East North Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
412-325-5700
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Offers Telehealth

Dr. Dulabh K. Monga is an Associate Professor of Medicine at Drexel University School of Medicine. She has been a GI Medical Oncologist practicing for the past 20 years. She is the lead for the Pancreas Cancer Disease Site Leadership Program at Allegheny Health Network and the Director of the Annual Pancreas Symposium. Dr. Monga is closely involved with the Cancer Bridges Support Group Program. She has done extensive clinical research and published original research, review articles and abstracts and mentored residents and fellows with their scholarly projects. She has served as the Principal Investigator for numerous clinical trials. She served as the Program Director of the Hematology Oncology Fellowship Program for 11 years. Dr. Monga has a passion for teaching medical students, residents and fellows and has been recognized for her dedication, mentorship, and excellence in teaching multiple times. Her passion is providing high quality multidisciplinary care that brings not only the best outcomes but maintains the quality of life of patients with pancreas cancer and other GI malignancies. She was awarded the Clinical Excellence Award from the National Pancreas Foundation in 2025. Dr. Monga has been named “Top Doctor” as chosen by her peers and featured in Pittsburgh Magazine for 2024 and 2025. Dr. Monga is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Monga is board certified in Medical Oncology, American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Larisa Greenberg

How do I make an appointment with Dr. Larisa Greenberg?

You can book an appointment with Dr. Larisa Greenberg by calling their office at 412-325-5700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Larisa Greenberg a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Larisa Greenberg is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Larisa Greenberg specialize in?

While Dr. Larisa Greenberg is a Oncology, they have specific expertise in Laryngeal Cancer, Angiosarcoma, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Larisa Greenberg participate in research or clinical trials?

Yes. Dr. Larisa Greenberg has published 6 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Larisa Greenberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Larisa Greenberg accept my insurance?

Dr. Larisa Greenberg accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 412-325-5700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenberg's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile